SCHEMBL5093253

SCHEMBL5093253

NCCNCCCc1ccc(Cl)cc1N1CCNCC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 8/20 0.45
HTR3E A5X5Y0 4/20 0.45
HTR3B O95264 4/20 0.45
HTR3D Q70Z44 4/20 0.45
HTR3C Q8WXA8 4/20 0.45
ADRB2 P07550 1/20 0.40
NCF1 P14598 1/20 0.40
DPP4 P27487 1/20 0.38
ADRB1 P08588 3/20 0.38
SIGMAR1 Q99720 2/20 0.38
HTR1A P08908 6/20 0.38
CYP1A2 P05177 5/20 0.38
CYP2D6 P10635 5/20 0.38
CYP3A4 P08684 4/20 0.38
CYP2C9 P11712 4/20 0.38
ALDH1A1 P00352 1/20 0.38
HTR2A P28223 2/20 0.38
HTR2C P28335 2/20 0.38
TP53 P04637 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5099978 0.88 ALDH1A1 (0.42) SIGMAR1ALDH1A1HTT
SCHEMBL5093305 0.85 POLB (0.48) HTR3ANCF1HTR1AALDH1A1HTR2A
SCHEMBL5093247 0.85 HTR3A (0.41) HTR3AHTR3EHTR3BHTR3DHTR3C
SCHEMBL5105811 0.84 ALDH1A1 (0.39) HTR1ACYP3A4ALDH1A1HTR6ESR1
SCHEMBL5099612 0.83 ALDH1A1 (0.36) SIGMAR1ALDH1A1
SCHEMBL27438244 0.80 HTR3A (0.55) HTR3AHTR3EHTR3BHTR3DHTR3C
SCHEMBL5099535 0.75 SLC6A4 (0.40) HTR3ASIGMAR1HTR1ASLC6A4HTR6
SCHEMBL5099392 0.73 SIGMAR1 (0.47) SIGMAR1CYP1A2CYP3A4CYP2C9ALDH1A1
SCHEMBL5099968 0.73 TPH1 (0.41) ALDH1A1HTT
SCHEMBL5093218 0.72 SIGMAR1 (0.42) SIGMAR1HTR1AALDH1A1HTR2AHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449477-B2 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) ELI LILLY AND COMPANY (US) 2008-11-11 US disclosed
US-20070037796-A1 e.g. 7-Phenyl-isoquinoline-5-sulfonic acid {2-[3 -(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; antiviral, antineoplastic, anticarcinogenic agents; neoplasms ELI LILLY AND COMPANY 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037796-A1 e.g. 7-Phenyl-isoquinoline-5-sulfonic acid {2-[3 -(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; antiviral, antineoplastic, anticarcinogenic agents; neoplasms POLI, HRAS, CHUK HTR3A 4687/4885HTR3E 4549/4885HTR3B 4633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.